Distribution of CATT end titres in primary and retreatment sleeping sickness cases at inclusion in the study.

<p>Distribution of CATT end titres in primary and retreatment sleeping sickness cases at inclusion in the study.</p

CATT positivity (%) during follow-up in primary HAT (left) and retreatment cases (right) who were cured or experienced treatment failure after current treatment.

<p>The number of samples that was tested is indicated, whiskers show 95% confidence intervals.</p

List of Ethiopian <i>T</i>. <i>evansi</i> isolates with data on origin and results in RoTat 1.2 PCR and EVAB PCR performed on DNA extracted from the buffy coat specimens from the infected camels.

<p>pos: positive, neg: negative.</p

SDS-PAGE analysis of the expression of rISG65, rLiTat1.3 and rLiTat1.5 by <i>Leishmania tarentolae</i> after purification following a single round of metal affinity chromatography.

<p>Coomassie stained 10% SDS-PAGE; Precision Plus Protein Unstained Standards, BioRad (M). Lane 1: rISG65, Lane 2: rLiTat1.3, Lane 3: rLiTat1.5. A = 1 μg and B = 10 μg protein.</p

Serum collection used in this study.

<p>Serum collection used in this study.</p

Percentage of kinetoplastic cells within <i>T</i>. <i>evansi</i> populations.

<p>Percentage of kinetoplastic cells visualised after DAPI staining and fluorescence microscopy within populations after 30 (black bars) and 60 days (grey bars) <i>in vitro</i> propagation. <i>T</i>.<i>b</i>.<i>g</i>. = <i>T</i>.<i>b</i>. <i>gambiense</i>, <i>T</i>.<i>b</i>.<i>b</i>. = <i>T</i>.<i>b</i>. <i>brucei</i>, <i>T</i>.<i>e</i> = <i>T</i>. <i>evansi</i>, MU = MCAM/ET/2013/MU.</p

Pairwise difference and <i>p</i> value of the Chi square between the areas under the curve recorded for the different antigens when tested with sera from 172 <i>T</i>.<i>b</i>. <i>g-</i>HAT patients, 119 non-<i>g-</i>HAT controls and 50 non-<i>r-</i>HAT controls.

<p>* = significantly different</p

Area under the curve (AUC) and its 95% confidence interval (CI), Youden index, percent sensitivity (Se %), percent specificity (Sp %) and their respective 95% CI recorded for the different antigens when tested with sera from 172 <i>g-</i>HAT patients, 119 non-<i>g-</i> HAT controls and 50 non-<i>r-</i>HAT controls.

<p>Area under the curve (AUC) and its 95% confidence interval (CI), Youden index, percent sensitivity (Se %), percent specificity (Sp %) and their respective 95% CI recorded for the different antigens when tested with sera from 172 <i>g-</i>HAT patients, 119 non-<i>g-</i> HAT controls and 50 non-<i>r-</i>HAT controls.</p

Receiver operator characteristic (ROC) curves and area under the curve (AUC) constructed from ELISA results obtained by testing sera from 172 <i>g-</i>HAT patients, 119 non-<i>g-</i>HAT controls and 50 non-<i>r-</i>HAT controls with nLiTat 1.3 (2 μg/ml), rLiTat 1.3 (4 μg/ml), nLiTat 1.5 (2 μg/ml), rLiTat 1.5 (4 μg/ml) and rISG65 (4 μg/ml).

<p>Receiver operator characteristic (ROC) curves and area under the curve (AUC) constructed from ELISA results obtained by testing sera from 172 <i>g-</i>HAT patients, 119 non-<i>g-</i>HAT controls and 50 non-<i>r-</i>HAT controls with nLiTat 1.3 (2 μg/ml), rLiTat 1.3 (4 μg/ml), nLiTat 1.5 (2 μg/ml), rLiTat 1.5 (4 μg/ml) and rISG65 (4 μg/ml).</p

Gel filtration of purified rISG65 on a Superdex 200 10/300 GL column (GE Healthcare Lifesciences) in sodium phosphate buffer, pH7.5, O.5 M NaCl.

<p>A. Molecular weight markers (Sigma-Aldrich MWGF100) 1 = thyroglobulin 669 kDa, 2 = apoferritin 443 kDa, 3 = β-amylase 200 kDa, 4 = alcohol dehydrogenase 150 kDa, 5 = bovine serum albumin 66 kDa, 6 = carbonic anhydrase 29 kDa. B. Elution profile of rISG following one round of metal affinity chromatography purification.</p